Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Correct me if I'm wrong BUT Navidea received Federal Grant money specifically for RIGS and the company started clinical trials with the University of Alabama back in December 2013 with said Federal Grant money. If the company accepted the grant money and started a trial, THEN THEY DAMN WELL BETTER NOT ABANDON RIGS AND THEY DAMN WELL BETTER UPDATE THE SHAREHOLDER ON RIGS SOONER THAN FAST! Knowing Brent Larson and Mark Pykett, they probably took all the grant money they could and just pocketed it. Maybe there is no clinical trial.
The company is underestimating the sanity of the average shareholder if they think they can continue to kick shareholders in the face and not push some over the edge...speaking for myself, I'm waaaaaay beyond my own limits. This whole reducing the 2014 revenue projection only 6 months later by $2 million (33%) seems like a deliberate smack to the shareholder JUST LIKE THE CREDE DEAL VALUING THE COMPANY AT 2.11 PER SHARE. Someone should have taken matters into their hands at least 12 months ago! EVERYTHING the company is DOING IS HELPING TO DESTROY THE SHARE PRICE!
The sad thing is, as the pps slides further and further, the next offering will be at a really low price and it will be 30,000,000 or more shares...think about that! In September 2013, they got 2.85 for 10,000,000 shares and we were under 2.00 in no time. NOW if they want to raise $30,000,000 we would be talking about 30,000,000 shares at 1.00 and a .50 share price within hours.
And even when Brent Larson is dismissed or terminated, he can STILL feed illegal information to his old shorts or new ones - too bad he wasn't on Flight 11 or Flight 175. He deserved to be there more than most.
That should be a nice price point to double your position at. I am wondering if the large blocks we saw today were short covering. Insider buys of 100,000+ shares seem unlikely with our mismanagement team. If the pps remains in the 1.00-1.10 range for weeks on end like I think it will, a gradual decline in the short interest may follow. If not, wtf are the shorts waiting for now? Claim victory and depart the field. Not covering now with tax loss selling imminent for so many longs and traders could be an opportunity the shorts could regret later IF Gonzalez can do something right AND DO IT SOON.
I bet Mark Pykett is laughing his ass off today at the shareholders of the company whose stock he managed to destroy. May Cheshire Connecticut style torture visit him, his wife, and the rest of his family.
Time for a Brent Larson bonus! As the share price gets lower and lower, Navidea executives should rape the shareholder in every possible way. Hey Brent! Here's an idea! Put out a PR that RIGS is being formally abandoned by the company! That might cut the pps in half from where it is now. After that, do another toxic financing deal of 100,000,000 shares for .45. The net effect of a deal that like would cut the price to a quarter. THIS WOULD MAKE YOU AND YOUR SHORT INTEREST FRIENDS A FORTUNE!
I'm sure Brent that you have even more destructive plans in mind than any shareholder can imagine!
Will Q1 of 2015 revenue be anywhere near $2 million (even with EU approval)? Seems dobutful to me - BUT I HAD FAITH THAT WE WOULD BE NEAR $1.9 million in Lymphoseek sales for Q3. I was quite mistaken. I already believe Q4 revenue will be $1.3 million or less, thanks to the recent guidance provided by hardworking Navidea executives. Can total 2015 revenues for Lymphoseek exceed $10 million? Seems unlikely today.
Brent Larson has been around the longest (more than 10 years) and knows all of the many little rude surprises STILL ahead (like the $539,000 in wasted Lymphoseek inventory we just learned of). He needs to be terminated from his far overcompensated position and SUED PERSONALLY for working with the shorts. Take his car, house, and shirt off of his back. Empty his bank accounts and find the million plus dollars he has been paid to sandbag his own company.
My theory on his illegal destroying of the company goes something like this: Larson has a private lunch in a state other than Ohio with several men that short stocks whom he all knows very well. He might have spelled out a few specifics about the failures to come, like, "We know that Lymphoseek won't sell significantly for the first decade" and tells these men simply, "Keep shorting until I call you and give the code to stop shorting." Afterall, with Larson himself knowing the company is headed nowhere, he doesn't even need to provide coming failure updates to the shorts by phone on a regular basis, he just has to warn them if anyone else in the company has accomplished something that could move the price more than a dime.
I posted it two days ago, and the next day, eterso3 on the Oldtimers Board in post #13288 said the same thing (and copperking23 seems also quite unhappy with Larson). Is he involved in the shorting (or just stupid)? I say he is both. I also say HE WILL NOT GET AWAY WITH IT! :)
Of course, Gonzalez is not to blame for anything YET.
An article to be released not too far in the future?
Taken from:
MEDICAL NEWS TODAY
March 19, 2016
"LYMPHOSEEK, the treatment that never was"
Three years ago, Navidea (formerly Neoprobe) gained FDA approval for Tilmanocept-99, specifically designed and indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma. Since March 2013 though, sales have only amounted to $9.3 million as the medical community worldwide has simply not taken to the product. "I just don't know what to make of it," said Allen Richards (Navidea's seventh CEO in the past three years) "We were so sure it would become the standard of care. In the end, all we did was fleece investors and create angry shareholders." Brent Larson, a long time Navidea employee was terminated and jailed in 2015 after it was revealed that he had illegally been feeding insider information to numerous large short sellers of the company for years, albeit to the company's near bankruptcy at present. With 375,000,000 shares outstanding from five new share offerings since the September 2013 Crede deal, and a current share price of .09, the future of this tiny biotech is more in doubt than ever.
The shorts do not have to exert much effort (if any) to hold the pps down today...Management has done a fine job of frustrating longs into throwing shares away. The shorts might be able to take a holiday for a whole week and the pps can drift down all on its own. Afterall, tax loss selling season is soon to come, the next quarterly report is obviously 3 months away, and there is no hint of anything positive coming that will help. Given the abominable sales for Q3, who should give a F*** about EU approval anyways?
LYMPHOSEEK HAS BEEN FDA APPROVED SINCE MARCH 2013 AND SALES ARE ONLY $1.1 million per quarter now?! I certainly understand why some think that more dilution is a real threat. Sales need to increase by a factor of 4 or 5 to eliminate such a threat.
UNACCEPTABLE!
Shareholder lawsuit time!
The stock market is higher than ever and NAVB is going absolutely nowhere. Larson needs some serious skull cinder block thrashing treatment, and that's just for starters...so does Thom the TOOL Tulip. The eternal torture of the NAVB shareholder needs to end. Start selling the product OR SELL THE F@@@@@G COMPANY TO SOMEONE THAT KNOWS WHAT YHE F@@@ THEY ARE DOING! The next short interest report will likely show an increase of 500,000 shares IMO.
The shorts act as if tomorrow we will see an 80% decline in revenues for the quarter. An increase toward the $2 million area is more likely, but even so, more shorting is imminent. Management had failed the NAVB shareholder. The only way this stock revives as early as tomorrow is with a quarterly revenue of $2.5 million AND a PR that RIGS is moving up to the next level. Maybe we'll hear about the next Crede deal instead!
One other thing...Navidea has CLEARLY shown that they have no idea how to market their miracle Lymphoseek. HOW THE HELL is the shareholder supposed to believe that they can sell any of the pipeline products if EVER approved? It sure seems like the shorts knew how incompetent Larson and Tulip are and decided to bet the farm on their slow progress across the board...and a great bet it has turned out to be!
Well, I was hoping for $1.9 million (at least) but this seems exceptionally unlikely...add to that, the volume is the lowest I can EVER recall with NAVB. 61,151 shares as of 2:26PM?! The market has really lost interest "in our tiny biotech."
With our October FDA approval, I think we might see a better Q4 than Q3, but with this F*****G company, anything negative that kicks shareholders in the face seems the best bet.
The stock is trading like society no longer wants to treat cancer - just let cancer victims (and NAVB shareholders) DIE!
Thanks Brent Larson.
Thanks Thom Tulip.
Thanks Julia Larson.
Thanks Rosalind Primmer (and I don't blame you for not taking the name Tulip) No one wants to buy Lymphoseek, why marry a Tulip?! LOL.
Intelius is a WONDERFUL resource!
Tax loss season ahead! More kicks in the face for shareholders over the next two months even if EU approval happens in 2014.
Great job management for making 2014 the worst for shareholders in more than 5 years. This year started with an announcement that salaries for Pykett, Tulip, and Larson would be cut...Given the unresponsiveness in the share price throughout the past year, deeper pay cuts SEEM MORE THAN CALLED FOR IN 2015.
Are you still smiling right now? The market is at an all-time high and G D NAVB is going down. It might be really simple though - If Platinum gives a F about NAVB, then Platinum WILL NEVER ALLOW another dilution or Crede deal ever again. Indeed, Platinum has the resources to fix the NAVB stock price all on their own. They could loan money to the company tax free or they could announce that they are buying shares on the open market. They can promote the company in ways the average investor can't imagine.
Regardless of the power that the BILLIONS of dollars affords them to address Navidea management's financial failures, I also bet they wish they had sold their entire position above $3 when they had their chance. Larson and Tulip don't inspire much faith and trust these days and these two have yet to pay for what they have done to shareholders. Shareholder revolt might not be far off, Gonzalez better stop shoving his face full of burritos and quesedillas and start earning his G D paycheck!
Boo, I still love your optimism, but the shorts have treated NAVB like a public f**k toy that they can molest and abuse at will...I would LIKE NOTHING MORE than to see the outrageous short interest blow up in their faces, but look at today's volume...79,000 shares. Longs should stop loaning shares out to the shorts. Companies like Ameritrade SHOULD NOT be legally allowed to loan out MY shares WITHOUT my permission and COMPENSATING ME as well.
EU approval is expected by year's end and we have a quarterly report next Thursday, yet we also have no buyers here at the moment. Volume came from out of nowhere yesterday which was nice to see.
Manocept may be the final key to this puzzle. The FDA likes Lymphoseek so much, it makes some intuitive sense that Manocept will eventually be the homerun that we all want - it just might be years and years away.
GLTA.
Boodog, that individual has 36,103 posts on ihub and only a few on NAVB, BUT ALL NAVB posts seem to be death chart/doom and gloom related. He moderates four boards and seems to like pharmaceutical stocks. Even so, he could be a short trying to kick our faces harder than management has, but either way, I'm not selling shares now.
Unfortunately, our new CEO was NOT such a big name that the company has immediately restored credibility at the top. I still maintain though, that basing compensation for Gonzalez on share price appreciation and Lymphoseek sales WAS A bleeping MUST!
GLTA.
I have to question the motives for posting doomsday chart interpretation when a poster has never posted anything else related to the stock on this board. After all, while my patience is gone with this company, even I know that sales will only be increasing significantly from here. The charts are the way they are from the excessive shorting...a squeeze would reverse all charts.
Imagine if Platinum gave Navidea an interest free loan INSTEAD of ever diluting again...it could sure burn the shorts. Even the FDA is coming out and saying how significant Lymphoseek is. Platinum can make choices in favor of Navidea (and all shareholders LIKE THEMSELVES) to crush the shorts and perhaps, Platinum is our best bet to turn this around. The more faith Platinum shows in the company, the more the market will give a D about it too...simple really.
A message to Rick Gonzalez:
STOP admiring the leather chair and fancy woodwork in your office and START ADDRESSING THE DISGUSTING SHARE PRICE RIGHT NOW!
Get on the G D street corner to sell Lymphoseek if you have to!
Boo, I know you are bullish on NAVB and I understand why. But I am still wondering something:
WHERE THE F--- are the insider buys?
Anyone?
I'm expecting an increase in the next two short position reports totaling at least 1.1 million shares between both reports. All of those recent dips back to 1.22 were undoubtedly more shorting, nothing more...so much the better. Now if the company can learn to SELL the product that it has received APPROVAL for, the shorts will feel it where the sun don't shine rather aggressively, otherwise, WE will continue to feel it into 2015 and beyond.
Tick tock.
Thanks for your sales projections boda - the total of your four quarters is right around $27 million - even higher than the high end of my estimate. This might be enough money to keep dilution away...
In my opinion, Platinum can take control of this situation anytime they want, but are not doing so yet. They have billions of dollars and in the end, they have the power and resources to make NAVB sink, swim, or fly...For now, they seem to be watching.
Gonzalez gets $750K in the event of a change of control. If I were he, I would be staying up till midnight and working weekends to find a buyer for the company at $3.00+ per share. If he can accomplish this, everyone but the shorts (BUT ESPECIALLY GONZALEZ HIMSELF) will be very happy.
Can we see 1.50 this week? I'd love to see 1.60, but I try to stay realistic with this company these days...LOL.
What are some estimates of company revenue for Lymphoseek sales in 2015? Assuming we get EU Approval, is $20-25 million AT A MINIMUM likely or possible? Serious question looking for serious answers, please. LOL.
I agree that the move should have started before now. Indeed, it should have started WEEKS ago!
Maybe instead of PDUFA run, the shorts are retreating a bit. It's a long long way to 26 million though. LOL.
WOW WOW WOW WOW!
The new CEO has bonuses and salary increases BASED ON STOCK PERFORMANCE! It's about time! Can we please adjust Tulip and Larson's pay immediately in the same good fashion?!
MUST READ (thanks Kent8692):
http://www.bizjournals.com/columbus/news/2014/10/15/navidea-hires-rick-gonzalez-as-ceo-from-spectrum.html?ana=twt
Thanks sts66.
From one boo to another...LOL...I like your optimism. I didn't really expect a delay, but sure enough, there were 200,000 more shares shorted than covered today (and the pps was held down for weeks on end leading up to today). The shorts have been at this for at least 3 years now...Maybe the new CEO has contacts and relationships with other pharmaceuticals that will yield good things.
Regardless of approvals and revenues though, I'm not happy with a pps of 2.27, let alone 1.27.
Europe has hurt the company considerably with all of the delay and BS...Lymphoseek should have been approved in Europe as of December 2013.
GLTA. Will we have a few days remaining in 2014 with the wind at our backs? I can dream.
Does anyone here know how to post a picture that is not from a web address that is from my computer instead? Please advise.
This stock has been trading almost like an FDA delay is coming, not necessarily an outright denial. NO, I am not a basher of Lymphoseek - only of the current mismanagement team that abuses shareholder money and cannot market Lymphoseek at all.
THIS APPROVAL IS (or was) SUPPOSED TO BE A GAME CHANGING EVENT to increase sales of Lymphoseek by multitudes and company revenue accordingly, yet the price action through today has only become weaker. I see several possibilities.
The shorts are relentless without knowledge of a denial/delay to come this week OR they know already somehow and we go under 1.00 with bad FDA news. With approval, I expect them to pound the hell out of the stock anyways and will be thrilled to see 1.40 with approval.
While 1.40 is disgusting territory for a stock that once traded well above 5.00, it is far better than the 1.20s and 1.30s we have seen for months.
In honor of the terrible job Tulip and Larson are doing when it comes to increasing shareholder value in Navidea, I changed my profile image today. I also have a very interesting picture to share.
Weekends are the best days for NAVB now. No matter how much harm Tulip and Larson do during the "work" week, the pps does not go down further on Saturday and Sunday.
A lawsuit against these two PERSONALLY is in order. Take the shirts off their backs, empty Julia's closet, take the toys right out of their children's bedrooms. When in comes to Thom, I'm sure that Erin Tulip, Bryn Tulip, Rosalind Primmer, and Amy Tulip have benefited at OUR EXPENSE FOR LONG ENOUGH!
The price action shows how inept and destructive these two are to the shareholder.
Approval this month was supposed to be the "game changer" yet the stock is trending down. The game seems to be changing for the worse alright - maybe Tulip the tool and Relentlessly lazy Larson have been promised yet another bonus if the pps can close under 1.00 for two days in a row.
Congratulations Tool and Lazy, your bonus seems within reach.
Thank you Fall1980 and inside for all of the Navidea finance calculation work...you guys did a great job of figuring out how bad the Crede deal was before most. I seriously think you gentlemen put more thought into company finances than the company itself. After all, the company just spends money day after day, year after year, without considering shareholders at all. Morons like Brent Larson would welcome another offering though, especially when it would guarantee himself a salary of $250K for three additional years even if company sales revenue were to fall to zero dollars.
Navidea needs to change their EXCEPTIONALLY poor financial management history right now by laying off at least 5 of the 45 people officially employed by Navidea, and perhaps even more layoffs would be helpful. If the pipeline is being curtailed or delayed or slowed down (or whatever the hell is happening) then it is time to cut the work force. The new American way is that as people get laid off around you,l YOU have to DO MORE.
Updates on RIGS and the remainder of the pipeline are also grossly overdue...What a farce this company has become. May the lawsuits happen sooner than later!
All appearances are, that regardless of FDA approval next week and EU approval by the end of 2014, this stock is headed under 1.00 within 4 months (maybe much sooner). In 2015 it seems as though nothing substantial is on the horizon if the pipeline has been slowed down. This means 2016 OR NEVER. What a great spot the company has put itself (and more importantly shareholders) in. Don't forget that tax loss selling season is never good for NAVB.
How wonderful for Pykett that he got $750K out of the Crede money, leaving even less for the company to work with.
The morons that run this company are so good at getting themselves additional compensation, I bet Brent Larson is calculating three or four years down the road to his unemployment checks of $400 per week after Navidea no longer exists and he has collected his own $500K severance for "a job poorly done."
I bet Julia is proud Brent. You test my patience Larson...
I hope you are right, but again, nothing negative will surprise me. One effing RIGS development could turn this all around and the company chooses to leave it undeveloped.
After watching this garbage stock carefully over the past 3 months, I am convinced that upon approval next week, the stock will get heavily shorted and close below 1.30 and might even close under 1.20. The volume has been so low most days that the shorts have not had to use many shares to hold the pps down - the company is failing shareholders all by itself.
One very bad thing about a low share price is that the company would have to sell many more shares to raise the same money. For instance, the infamous and destructive Crede deal raised $30 million with 10 million shares sold. I try not to imagine the impact on the share price if the company needed to raise another $30 million with the next offering - this would mean that they would have to sell 22,727,272 shares at today's disgusting pps of 1.32. I bet the pps would be right around .75 once the deal was announced and probably never recover.
Mark my words now, the stock is not going to recover. The sarcasm on Yahoo sums it all up quite well. Maybe the company is going to do a private offering just to shorts of 26 million shares at a dime each. The shorts could cover and the company could crush its own shareholders once and for all. Nothing would surprise me.
And fwiw, I had oodles of inappropriate words to fit into this post here and there, but since I want this post to survive I left out those words. Wait till Wednesday and you can say those words for yourself.
It's time for new management and/or shareholder lawsuits. And one other thing, while I don't expect an FDA denial next week, anything seems possible with this mismanagement team.
The stock is trading like garbage...why would ANYONE pay 10 when 3 or 4 is a distant memory?
This stock is trading like absolute garbage. The market could care less about Lymphoseek even if every galaxy and universe in existence approves it. We have been defrauded by overpaid garbage management.
Pykett knew the Crede deal would ruin the stock but he also knew he would get a huge severance and seemingly did the deal in part to move on and rob shareholders further.
Tulip and Larson will find a way to get a bonus even if we get an FDA denial next week and an EU denial next month.
Zelkuschabo is spot on with his sentiment on the Yahoo board.
The Oldtimers are a weeeee bit preoccupied with Martin and the distant past. Is Martin the only thing they can talk about in the present and the damage Marty did 3+ years ago?!
YES YES YES Martin S. is responsible for smearing the company and stock price from 5.40 to 3.00. Agreed. But so what? That was 3 years ago...Much more recently
IT WAS SOLELY THE COMPANY'S MALICIOUS OWN THOUGHTLESS ACTION to raise $30 million through CREDE at the cost of over $100 million to shareholders. THERE IS ABSOLUTELY NO HINT OF RECOVERY FROM THE DAMAGE THE COMPANY HAS DONE TO ITSELF OVER THE PAST 12 MONTHS. INDEED, THE STOCK HAS ONLY BECOME WEAKER.
What's next? A buyout offer for $0.70 per share and the company jumps on it?
I have mentioned shareholder lawsuits in the past and I think it is time to start such talk again!
This stock seems to be headed no where in 2015, even with the two expected and anticipated regulatory approvals. And we still have tax loss selling season to look forward to!
It is downright sad that all those journalists have been beheaded by ISIL when Ray Leonard is so much more deserving of the fate that the journalists experienced.
How many hundreds of millions of dollars of shareholder money has Ray Leonard screwed away?
2014 is almost gone with no progress at all. Soon the entire concession will be lost due to inaction.
Zelkuschabo has put up some excellent posts on Yahoo and I wish he would come to this board.
Improve? Really? How in the hell is it possible that with an October PDUFA coming in 3 weeks that is the most significant for Lymphoseek so far, the company is trading at 1.24 and is in a PDUFA decline instead of in the middle of a PDUFA run? Shorts continue to control the stock AND the company continues to line their own pockets with millions of dollars in UNEARNED bonus money.
At this time, I would like to see a shareholder referendum where we get to vote on HUGE SALARY CUTS OF AT LEAST 75% for Tulip, Larson, and everyone else that is doing nothing for the shareholders they represent.
Tulip earning $90K instead of over $300K seems much more appropriate.
Larson earning $65K instead of $250K seems too generous still, but would teach him to earn his way back to a six-figure salary.
Disgusting performance from a scam of a company.
Good post BooDog, but I want to know why the company is releasing good news consistently at the worst times for the share price and investor. We have seen poor judgement repeatedly from this company...On the bright side, this implies that we get FDA approval next month or sooner.
And if Europe ever gets their head out of their F hole, we'll have approval there too.
1.46 is garbage territory though. Still a long way back to 2.50 or higher.